116 related articles for article (PubMed ID: 36568633)
1. Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET.
Chau M; Swarbrick N; Lee S
Urol Case Rep; 2023 Jan; 46():102300. PubMed ID: 36568633
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Case Report:
Fan J; Liang H; Zhang X; Chen X; Duan X; Li L; He D; Wu K
Front Oncol; 2021; 11():683343. PubMed ID: 34055650
[TBL] [Abstract][Full Text] [Related]
4. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS;
Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050
[TBL] [Abstract][Full Text] [Related]
5. Case Report:
Li Y; Li Y; Dong S; Chen J; Yang P; Li J
Front Oncol; 2022; 12():881896. PubMed ID: 35530336
[TBL] [Abstract][Full Text] [Related]
6. Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.
McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ
Adv Urol; 2021; 2021():1544208. PubMed ID: 34456998
[TBL] [Abstract][Full Text] [Related]
7. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
8. Prostate penile metastasis: Incidence and imaging pattern on
Tatkovic A; McBean R; Schoeman J; Wong D
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):499-504. PubMed ID: 32449823
[TBL] [Abstract][Full Text] [Related]
9. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
10. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
11. Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (
Farhan C; Mirzaei S
Asia Ocean J Nucl Med Biol; 2021; 9(2):180-182. PubMed ID: 34250148
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
13. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
14. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Role of
Shen K; Liu B; Zhou X; Ji Y; Chen L; Wang Q; Xue W
Front Oncol; 2021; 11():683793. PubMed ID: 34395251
[TBL] [Abstract][Full Text] [Related]
16. The Added Value of
Chen R; Wang Y; Zhu Y; Shi Y; Xu L; Huang G; Liu J
J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
[No Abstract] [Full Text] [Related]
17. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
18. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
19. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
20. Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.
Bergamini M; Dalla Volta A; Caramella I; Bercich L; Fisogni S; Bertoli M; Valcamonico F; Grisanti S; Poliani PL; Bertagna F; Berruti A
Front Oncol; 2022; 12():937713. PubMed ID: 35936689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
